Related Experiment Video
Updated: Apr 10, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
YM155 exerts a growth inhibitory effect on human osteosarcoma in vitro and in vivo
Zhuo Zhang1, Lianjun Ma1, Jincheng Wang2
1Department of Orthopedics, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China.
Abstract:
YM155, a novel small-molecule inhibitor of survivin, is known to exert antitumor effects on various cancers, including breast, prostate and lung cancer. However, there are few studies describing the inhibitory effect of YM155 on human osteosarcoma (OS) which highly expresses survivin. Here, we tested the effects of YM155 on OS cells by several in vitro experiments. It was found that YM155 inhibited cell proliferation, colony formation, migration and invasion, induced cell apoptosis, as well as increased caspase-3, -8 and -9 activity in the OS cell lines in a dose-dependent manner. We also found that YM155 suppressed Mcl-1 and survivin expression without affecting the expression of anti-apoptotic proteins X-linked inhibitor of apoptosis (XIAP) and Bcl-2. In addition, YM155 decreased phosphoinositide 3-kinase (PI3K) and AKT expression without effecting total PI3K and AKT in the OS cell lines, which contributed to suppression of OS tumor growth at least in part. In addition, YM155 also suppressed tumor growth in vivo, reducing the size of OS MG63 cell xenografts. Taken together, the findings revealed that YM155 suppresses the tumor growth of OS in vitro and in vivo, suggesting that YM155 has potential as a therapeutic agent for the treatment of OS.
Insights
YM155, a survivin inhibitor, effectively suppressed osteosarcoma (OS) cell growth, apoptosis, and metastasis in vitro. This novel therapeutic agent also demonstrated in vivo tumor suppression, indicating potential for OS treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Survivin is highly expressed in human osteosarcoma (OS).
- YM155 is a novel small-molecule inhibitor of survivin with known antitumor effects in various cancers.
- Limited research exists on YM155's efficacy in human osteosarcoma.
Purpose of the Study:
- To investigate the inhibitory effects of YM155 on human osteosarcoma (OS) cells.
- To evaluate the molecular mechanisms underlying YM155's action in OS.
- To assess the therapeutic potential of YM155 for OS treatment.
Main Methods:
- In vitro experiments assessing cell proliferation, colony formation, migration, invasion, and apoptosis.
- Western blot analysis to evaluate protein expression (Survivin, Mcl-1, XIAP, Bcl-2, PI3K, AKT).
- In vivo xenograft studies using OS MG63 cell lines.
Main Results:
- YM155 inhibited OS cell proliferation, colony formation, migration, and invasion in a dose-dependent manner.
- YM155 induced apoptosis and increased caspase activity, while suppressing Mcl-1 and survivin expression.
- YM155 decreased PI3K/AKT signaling and suppressed tumor growth in vivo.
Conclusions:
- YM155 effectively suppresses osteosarcoma growth both in vitro and in vivo.
- YM155 exerts its effects by inhibiting survivin and Mcl-1, and modulating PI3K/AKT pathways.
- YM155 shows significant potential as a therapeutic agent for osteosarcoma treatment.
